The COVID-19 pandemic is an ongoing global challenge for public health systems. Ultrasensitive and early identification of infection is critical in preventing widespread COVID-19 infection by presymptomatic and asymptomatic individuals, especially in the community and in-home settings. We demonstrate a multiplexed, portable, wireless electrochemical platform for ultra-rapid detection of COVID-19: the SARS-CoV-2 RapidPlex. It detects viral antigen nucleocapsid protein, IgM and IgG antibodies, as well as the inflammatory biomarker C-reactive protein, based on our mass-producible laser-engraved graphene electrodes. We demonstrate ultrasensitive, highly selective, and rapid electrochemical detection in the physiologically relevant ranges. We successfully evaluated the applicability of our SARS-CoV-2 RapidPlex platform with COVID-19-positive and COVID-19-negative blood and saliva samples. Based on this pilot study, our multiplexed immunosensor platform may allow for high-frequency at-home testing for COVID-19 telemedicine diagnosis and monitoring.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- low cost
- high frequency
- label free
- coronavirus disease
- gold nanoparticles
- healthcare
- high throughput
- loop mediated isothermal amplification
- mental health
- molecularly imprinted
- single cell
- oxidative stress
- transcranial magnetic stimulation
- mass spectrometry
- sensitive detection
- high resolution
- carbon nanotubes
- emergency department
- protein protein
- adverse drug